CounterACT Website |
---|
Abstracts for CounterACT projects are available via the CRISP database
Research Centers of Excellence
Gary R. Grotendorst, Ph.D.
Lovelace Biomedical & Environmental Research Institute
Identification of Therapeutics for the Treatment of Sulfur Mustard Injury
Phage Display Screening for Antibody Ligands to Sulfur Mustard Protein Adducts *
Jeffrey D. Laskin, Ph.D.
UMDNJ - Robert Wood Johnson Medical School
UMDNJ/Rutgers University CounterACT Research Center of Excellence
Polymer Nanogel Aggregates for Targeted Lung Delivery *
David E. Lenz, Ph.D.
U.S. Army Medical Research Institute of Chemical Defense
Center for Catalytic Bioscavenger Medical Defense Research
Sadis Matalon, Ph.D.
University of Alabama at Birmingham
Novel Treatments of Chlorine Induced Injury to the Cardio-Respiratory Systems
Steven Patterson, Ph.D.
University of Minnesota Twin Cities Center for Drug Design
Combined Use of Cobinamide and a 3-Mercaptopyruvate Prodrug for Cyanide Poisoning
Carl W. White, M.D.
National Jewish Medical and Research Center
Novel Antioxidant Therapeutics for Sulfur Mustard Toxicity
Catalytic Antioxidants for Chlorine Gas Lung Toxicity *
Individual Research Projects and Small Business Innovation Research
Edson X. Albuquerque, M.D., Ph.D.
University of Maryland School of Medicine
Age and Sex Effects on Nerve Agent Damage to the Brain and Antidotal Therapies
Behavioral Effects of Low Doses of Nerve Agents Are Counteracted by Galantamine: Potential Molecular Mechanisms *
Tamas Bartfai, Ph.D.
Scripps Research Institute
Developing GalR1/2 Agonists to Treat Nerve Gas Induced Seizure
Gerry R. Boss, M.D.
University of California, San Diego
Preclinical and Clinical Studies of Cobinamide, a New Cyanide Detoxifying Agent
Maria F.M. Braga, D.D.S., Ph.D.
Uniformed Services University of the Health Sciences
Efficacy of GluR5 Antogonists Against Soman-Induced Seizures and Neuropathology
John R. Cashman, Ph.D.
Human BioMolecular Research Institute
Biosensor for Real-Time Chemical Monitoring
William Catterall, Ph.D.
University of Washington
Receptor Sites and Antagonists for Paralytic Neurotoxins
Scorpion Toxin Antagonists *
Robert J. DeLorenzo, M.D., Ph.D., M.P.H.
Virginia Commonwealth University
Counter Measures Against Acetylcholine Receptor Activated Status Epilepticus
Development of BAPTA-AM as a Counteract Agent *
Raymond J. Dingledine, Ph.D.
Emory University School of Medicine
Prostanoid Modulators that Reduce Brain Injury and Inflammation after Seizures
Marion F. Ehrich, Ph.D.
VA-MD Regional College of Veterinary Medicine Virginia Tech
Fullerenes Counteracting Organophosphorus Threats
Pedro A. Ferchmin, Ph.D.
Universidad Central del Caribe
Protection Against Organophosphate Neurotoxins by Tobacco Cermbranoids
Byron D. Ford, Ph.D.
Morehouse School of Medicine
Neuroprotective Roles for Neuregulins in Neurotoxin-Mediated Neuronal Injury
Richard K. Gordon, Ph.D.
Walter Reed Army Institute of Research
Next Generation Oxime Therapeutic for Chemical Agent Inhibited CNS (Brain) ChEs
Kisholoy Goswami, Ph.D.
InnoSense, LLC
Fiber Grating-Based Chemoselective and Reversible Sensor Array
Michael D. Gunn, M.D.
Duke University
Prevention of Inflammatory Lung Injury After Chlorine Exposure
Gary W. Hoyle, Ph.D.
University of Louisville
Novel Therapies for Chlorine-Induced Lung Injury
Sven-Eric Jordt, Ph.D.
Yale University
Sensory Neural Mechanisms of Pulmonary Agent and Vesicant Toxicity
Jaideep Kapur, M.D., Ph.D.
University of Virginia HSC
Mechanism and Treatment of Nerve Agent-Induced Seizures
George D. Leikauf, Ph.D.
University of Pittsburgh
Functional Genomics of Chemical -Induced Acute Lung Injury
Yuehe Lin, Ph.D.
Battelle Pacific Northwest Laboratories
Innovative Biomonitoring Device for Rapid Diagnosis of Exposure to Nerve Agents
Oksana Lockridge, Ph.D.
Eppley Inst. For Res. In Cancer/Allied Diseases
University of Nebraska Medical Center
Mass Spectrometry in Clinical Diagnosis of Nerve Agent Exposure
Michael C. MacLeod, Ph.D.
University of Texas M.D. Anderson Cancer Center
Detoxification of Electrophilic Chemical Threat Agents by Nucleophilic Scavengers
Calum A. MaCrae, M.D., Ph.D.
Massachusetts General Hospital
Unbiased Screens in Zebrafish for New Classes of Cyanide Countermeasure
Sadis Matalon, Ph.D.
University of Alabama at Birmingham
Prevention and Treatment of Chlorine Gas Induced Injury to the Pulmonary System
Mohammad Modarres-Zadeh, Ph.D.
Cleveland Medical Devices Inc.
Field Deployable, Automatic, EEG Seizure Detector and Brain Dysfunction Monitor
Jon O. Nagy, Ph.D.
Nagy Consulting
Development of a Selective Biosensor for Detecting Organophosphate Exposure
Madhusoodana Nambiar, Ph.D.
Walter Reed Army Institute of Research
Therapeutics Against Chemical Threat Induced Respiratory Toxicity
Steven Patterson, Ph.D.
University of Minnesota Twin Cities
Center for Drug Design
Countermeasures Against Chemical Threats: Countermeasures Against Cyanide
James Peterson, Ph.D.
University of Pittsburgh
Acute Cyanide Toxicity, Complex IV, NO, & Nitrite
Randall T. Peterson, Ph.D.
Massachusetts General Hospital
Rapid Development of in vivo Models for Countermeasure Discovery:Organophosphate
Matthew R. Redinbo, Ph.D.
The University of North Carolina at Chapel Hill
Novel Protein-Based Therapeutics for Nerve Agent Detoxification
Exogenous Reactivators and Chemical Modifications of Designed Nerve Agent Hydrolyzing Human Carboxylesterase 1 Enzymes *
Richard L. Rotundo, Ph.D.
University of Miami Miller School of Medicine
Induced Therapeutic Overexpression of Acetylcholinesterase in vivo
David L. Sherman, Ph.D.
Infinite Biomedical Technologies, LLC
Automated Seizure Detection Following Nerve Agent Exposure
Palmer W. Taylor, Ph.D.
University of California, San Diego
Oxime-Assisted Catalysis of Organophosphates and Reactivation of AChE
Enhancing the Efficacy of Butyrylcholinesterase as a Plasma Scavenging Agent *
John K. Troyer, Ph.D.
PharmAthene, Inc.
Novel Therapeutic Agent to Treat Nerve Agent Exposure after Civilian Attack
James R. Wild, Ph.D.
Texas A&M University
Catalytic Bioscavengers with Broad Specificity Against OP Nerve Agents
Scott B. Wilson
Persyst Development Corporation
A First-Responder EEG Device for Seizure Management in a Nerve Gas Attack
Ruben Boado, Ph.D.
ArmaGen Technologies, Inc.
Targeted Paraoxonase Fusion Protein as a Neurotherapeutic for Nerve Gas Agents
Contracts, Clinical Trials, and Inter-Agency Agreements
Carol Green, Ph.D., D.A.B.T.
SRI International
CounterACT Preclinical Development Facility
H. Steve White, Ph.D.
University of Utah
Anticonvulsant Screening Program - New Countermeasures Screening Services
Robert Silbergleit, MD
University of Michigan
Clinical Trial through NINDS Network
Intramuscular midazolam versus intravenous lorazepam in the pre-hospital treatment of status epilepticus (the RAMPART trial)
Jack M. Baggett, Ph.D.
US Army Medical Research Institute of Chemical Defense
Inter-Agency Agreement between the National Institutes of Health and the Department of Defense
Chemicals affecting skin, eyes & mucous membranes - toxic vesicants and industrial chemicals
Chemicals affecting the nervous system - anticonvulsants and neuroprotectants
Cyanide diagnostics and efficacy testing of next generation cyanide antidotes
Chemicals affecting the respiratory tract - pulmonary toxicants
* Supplemental research supported by the 2008 CounterACT Administrative Supplement Program (Please contact PI directly for additional information about these efforts).
Last updated May 04, 2009